related_education

Sleep and Cognition in Older Adults

The purpose of this study is to determine how sleep is affected in both healthy aging and neurodegenerative processes. The study aims to determine whether sleep quality alters performance on cognitive tasks in older adults and whether this relationship changes with mild to moderate cognitive impairments.

Summary

  • Study director: Christine Walsh, PhD
  • Sponsor: National Institute of Health (NIH) and the Tau Research Consortium
  • Recruiting?: Yes
  • Official study title: The Relationship Between Sleep and Cognition in Older Adults

Join a Supportive Care Trial

Quality of Life Trials or Supportive Care Trials are research studies to evaluate improving the health, care or quality of life for people, typically without using study drugs or devices. UCSF's Memory and Aging Center (MAC) runs selected supportive trials for people with neurodegenerative disease. Your participation helps us evaluate these interventions. If one of our trials looks interesting to you, please talk with your doctor or contact the study team to see if it is appropriate for you.

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

The goal of this study is to support the development of FTLD therapies through a multi-site research consortium headquartered at UCSF. The study aims to determine the clinical, genetic, and biomarker profiles of FTLD syndromes where there is a strong correlation between clinical syndrome and underlying pathology (FTD-ALS, PSP, and semantic variant PPA (svPPA)). The study also aims to determine the natural history of familial FTLD using novel clinical measures.

Summary

  • Study directors: Adam Boxer, MD, PhD and Howard Rosen, MD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Progressive Supranuclear Palsy Trial of Oral Salsalate

Salsalate has been marketed for decades in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorders, but this is the first time salsalate will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of oral salsalate in people with PSP.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02422485

Progressive Supranuclear Palsy Trial of Plasma Transfusions

Young healthy male donor plasma is commonly used to correct clotting deficiencies, but this is the first time it will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of donor plasma transfusions in patients with PSP.

Summary

  • Study director: Richard Tsai, MD, MBA
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy

Frontotemporal Dementia with Granulin Mutation Trial of a Histone Deacetylase Inhibitor

The aim of this trial is to evaluate the safety and tolerability of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin mutation and to see if it causes a change in plasma concentrations of progranulin.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: FORUM Pharmaceuticals
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Huntington’s Disease Trial of Laquinimod (LEGATO-HD)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of laquinimod which is hypothesized to decrease inflammatory processes that occur in the brain in Huntington’s disease.

Summary

  • Study director: Michael Geschwind, MD, PhD
  • Sponsor: Teva Branded Pharmaceutical Products R&D, Inc
  • Recruiting?: February 2015
  • Official study title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease

Familial Progressive Supranuclear Palsy (FamPSP)

The goal of this study is to identify rare genetic variants as risk factors for progressive supranuclear palsy (PSP). By studying patients with PSP and their relatives affected by related conditions, we hope to identify genes that are involved in PSP and related disorders.

Summary

Purpose of Study

Early Onset and Atypical Alzheimer’s Disease

Approximately 5% of patients with Alzheimer’s disease develop symptoms before age 65, without a known genetic cause. In this study, we use comprehensive clinical evaluations, cerebrospinal fluid (optional) and genetic analyses, and MRI and PET imaging to improve our understanding and diagnosis of early onset and atypical Alzheimer’s disease.

Summary

  • Study director: Gil Rabinovici, MD
  • Sponsor: National Institute on Aging
  • Official study title: Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration

Care Ecosystem: Navigating Patients and Families through Stages of Care

Most dementia care today is crisis-oriented, intermittent and impersonal. The Care Ecosystem is a proactive model that emphasizes coordinated, continuous, and personalized care and aims to improve health and satisfaction for patients and their caregivers. The intervention will also try to reduce avoidable emergency room visits and hospitalizations, and delay entry into a nursing home.

 

Enrolling now! (click to see if you qualify)

Syndicate content